Metric Deep Dive: Understanding Zentalis Pharmaceuticals Inc (ZNTL) Through its Ratios

Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.

After finishing at $1.49 in the prior trading day, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) closed at $1.48, down -0.67%. In other words, the price has decreased by -$0.67 from its previous closing price. On the day, 0.71 million shares were traded. ZNTL stock price reached its highest trading level at $1.515 during the session, while it also had its lowest trading level at $1.47.

Ratios:

Our goal is to gain a better understanding of ZNTL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.99 and its Current Ratio is at 7.99. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.

On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 30 ’25 when Myers Scott Dunseth bought 21,000 shares for $1.40 per share. The transaction valued at 29,373 led to the insider holds 281,192 shares of the business.

Bruns Ingmar bought 20,000 shares of ZNTL for $45,656 on Feb 06 ’25. The Chief Medical Officer now owns 36,629 shares after completing the transaction at $2.28 per share. On Feb 11 ’25, another insider, Cam Gallagher, who serves as the Former Director of the company, bought 687 shares for $2.00 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 106760544 and an Enterprise Value of -155353536. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.97 while its Price-to-Book (P/B) ratio in mrq is 0.39. Its current Enterprise Value per Revenue stands at -5.783 whereas that against EBITDA is 0.912.

Stock Price History:

The Beta on a monthly basis for ZNTL is 1.76, which has changed by -0.5271566 over the last 52 weeks, in comparison to a change of 0.16461086 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $5.44, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is 6.86%, while the 200-Day Moving Average is calculated to be -27.57%.

Shares Statistics:

The stock has traded on average 929.57K shares per day over the past 3-months and 575810 shares per day over the last 10 days, according to various share statistics. A total of 72.14M shares are outstanding, with a floating share count of 56.51M. Insiders hold about 21.66% of the company’s shares, while institutions hold 69.36% stake in the company. Shares short for ZNTL as of 1753920000 were 4708124 with a Short Ratio of 5.06, compared to 1751241600 on 5070961. Therefore, it implies a Short% of Shares Outstanding of 4708124 and a Short% of Float of 8.1499994.

Leave a Reply

Your email address will not be published. Required fields are marked *

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.